Table 1 Patient and treatment characteristics for all patients (left panel), ARO-analogue subgroup (middle panel) and HPVOPC (right panel)
Factors | All patients | ARO-analogue | HPVOPC | |||
|---|---|---|---|---|---|---|
n = 184 | n = 92 | n = 25 | ||||
Number | Percent | Number | Percent | Number | Percent | |
Age | ||||||
< 45 | 4 | 2.2 | 3 | 3.3 | 1 | 4.0 |
45–54 | 30 | 16.3 | 23 | 25.0 | 1 | 4.0 |
55–64 | 66 | 35.7 | 37 | 40.2 | 8 | 32.0 |
65–74 | 53 | 28.8 | 23 | 25.0 | 9 | 36.0 |
75–84 | 27 | 14.7 | 6 | 6.5 | 6 | 24.0 |
> 85 | 4 | 2.2 | 0 | 0.0 | 0 | 0.0 |
Sex | ||||||
male | 143 | 77.7 | 71 | 77.2 | 20 | 80.0 |
female | 41 | 22.3 | 21 | 22.8 | 5 | 20.0 |
Diagnosis class | ||||||
first diagnosis | 161 | 87.5 | 83 | 89.2 | 22 | 88.0 |
disease recurrence | 23 | 12.5 | 9 | 9.8 | 3 | 12.0 |
Localization | ||||||
Oropharynx | 78 | 42.4 | 40 | 43.5 | 25 | 100.0 |
Larynx | 37 | 20.1 | 17 | 18.5 | 0 | 0.0 |
Hypopharynx | 35 | 19 | 20 | 21.7 | 0 | 0.0 |
Oral cavity | 34 | 18.5 | 15 | 16.3 | 0 | 0.0 |
Primary Tumor (T) | ||||||
cT1–2 | 37 | 20.1 | 13 | 14.1 | 3 | 12.0 |
cT3–4 | 147 | 79.9 | 79 | 85.9 | 22 | 88.0 |
Lymph Nodes (N) | ||||||
cN0-cN2a | 72 | 39.1 | 35 | 38.0 | 8 | 32.0 |
cN2b-cN2c | 105 | 57.1 | 53 | 57.6 | 17 | 68.0 |
cN3 | 7 | 3.8 | 4 | 4.3 | 0 | 0.0 |
Metastasis (M) | ||||||
cM0 | 184 | 100.0 | 92 | 100.0 | 25 | 100.0 |
cM1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Stage 7th edition (8th edition HPVOPC a) | ||||||
UICC I | 1 | 0.5 | 1 | 1.1 | 0 (2a) | 0.0 (8.0 a) |
UICC II | 8 | 4.3 | 5 | 5.4 | 1 (10 a) | 4.0 (40.0 a) |
UICC III | 30 | 16.3 | 15 | 16.3 | 4 (13 a) | 16.0 (52.0 a) |
UICC IV | 145 | 78.8 | 71 | 77.2 | 20 (0 a) | 80.0 (0.0 a) |
Grading | ||||||
G1 | 7 | 3.8 | 3 | 3.3 | 0 | 0 |
G2 | 89 | 48.8 | 43 | 46.7 | 9 | 36.0 |
G3 | 83 | 45.8 | 45 | 48.9 | 16 | 64.0 |
Gx | 5 | 2.7 | 1 | 1.1 | 0 | 0 |
p16 staining | ||||||
Positive | 35 | 19.0 | 21 | 22.8 | 25 | 100.0 |
Negative | 121 | 65.8 | 59 | 64.1 | 0 | 0.0 |
unknown | 28 | 15.2 | 12 | 13.0 | 0 | 0.0 |
smoking history | ||||||
< 10 pack-years | 10 | 5.4 | 3 | 3.3 | 2 | 8.0 |
> 10 pack-years | 99 | 53.8 | 49 | 53.3 | 7 | 28.0 |
unknown | 75 | 40.8 | 40 | 43.5 | 16 | 64.0 |
Therapeutic Dose | ||||||
Median | 70 Gy | 70 Gy | 70 Gy | |||
> = 66 Gy | 179 | 97.3 | 90 | 97.8 | 25 | 100.0 |
< 66 Gy | 5 | 2.7 | 2 | 2.2 | 0 | 0.0 |
GTV volume | ||||||
available | 174 | 94.6 | 87 | 94.6 | 24 | 96.0 |
missing | 10 | 5.4 | 5 | 5.4 | 1 | 4.0 |
range (in cc) | 2–789 | 2–789 | 18–359 | |||
mean (in cc) | 61 | 106 | 107 | |||
Chemotherapy | ||||||
no | 18 | 9.8 | 0 | 0.0 | 1 | 4.0 |
yes | 166 | 90.2 | 92 | 100.0 | 24 | 96.0 |
MMC / 5FU | 92 | 50 | 92 | 100.0 | 18 | 72.0 |
MMC mono | 28 | 15.2 | 0 | 0.0 | 2 | 8.0 |
Platin based | 26 | 14.1 | 0 | 0.0 | 1 | 4.0 |
Cetuximab mono | 20 | 10.9 | 0 | 0.0 | 3 | 12.0 |
Chemo completed | 135 | 81.3 | 84 | 91.3 | 20 | 83.3 |
Chemo stopped | 31 | 18.7 | 8 | 8.7 | 4 | 16.7 |
patient refused | 1 | 1 | 0 | |||
worsening condition | 15 | 5 | 4 | |||
cytopenia | 9 | 1 | 0 | |||
reaction to chemo | 6 | 1 | 0 | |||
Causes of death | ||||||
tumor related | 50 | 27 | 1 | |||
comorbidities | 40 | 21 | 6 | |||
therapy-associated | 0 | 0 | 0 | |||
second primary | 11 | 5 | 0 | |||
unknown | 12 | 5 | 1 | |||